slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 10,141-10,170
Pages 473
Rows per page 30
Slide function
10,141-10,170 of 14,162
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
104
The seesaw diagram is a visual metaphor for the mechanism of action and its unintended side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
105
The slide uses a direct comparison of drug mechanisms to challenge the target company's safety claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
107
The slide uses red boxes to draw attention to the specific data points being compared.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
109
The slide uses direct quotes from medical experts to highlight a potential flaw in the company's clinical approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
110
The slide uses a Q&A transcript format to highlight specific patient cases that suggest a severe, long-term adverse effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
114
The red box highlights the specific data point (Week 0 to Week 13) where the pooling occurs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
115
The slide uses a red box and annotations to highlight the drop in sample size (n=125 to n=103) at week 13, suggesting data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
116
The slide uses a red box and arrow to draw attention to the increase in HbA1c between week 0 and week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
117
The slide uses a line chart with error bars to argue that the mean value hides adverse patient outcomes. It highlights the 1-standard deviation range and extrapolates to 2-standard deviations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
121
The slide uses a direct quote from a medical paper to highlight a discrepancy between the company's claim and the reported data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c values) have been altered.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
130
The slide uses a line chart with error bars to compare 'Original Data' vs 'New Data' to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
131
Uses a 'before-after' comparison to highlight data inconsistency as evidence of fraud.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit